Most Read Articles
Pearl Toh, 12 Jan 2021
Adding the CDK4/6 inhibitor abemaciclib to an endocrine therapy of fulvestrant extends overall survival (OS) compared with fulvestrant alone in East Asian patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who have progressed on prior endocrine therapy, consistent with results from the overall population, updated analysis of the global, phase III MONARCH 2 study has shown.

Dysmenorrhea linked to presence, severity of chronic pain

17 Sep 2020

There appears to be an association between dysmenorrhea and chronic pain, but whether primary dysmenorrhea heightens the risk for chronic pain remains to be proven, according to the results of a systematic review and meta-analysis.

Of the 9,452 studies identified, 32 met the eligibility criteria, with 14 reporting associations between dysmenorrhea and chronic pelvic pain and 20 between dysmenorrhea and chronic nonpelvic pain. Seven studies examined primary dysmenorrhea and endometriosis-related dysmenorrhea. Fifty-six percent of the studies were categorized as moderate quality, 30 percent as poor, and 12.5 percent as high.

Dysmenorrhea positively correlated with both the presence and severity of chronic pelvic and nonpelvic pain conditions. Analysis of 6,689 women from eight studies revealed 2.43 times (95 percent confidence interval [CI], 1.98–2.99; I2, 42 percent) higher odds of having dysmenorrhea among participants with chronic pelvic pain than with those without.

Moreover, 11 studies involving 3,750 women reported 2.62 times (95 percent CI, 1.84–3.72; I2, 72 percent) higher odds of having dysmenorrhea among participants with chronic nonpelvic pain compared with those without.

Dysmenorrhea correlated with 2.50 times (95 percent CI, 2.02–3.10) the odds of chronic pain overall. Such association did not differ by chronic pain vs chronic nonpelvic pain, community vs clinical populations, or different geographical regions.

“Given that adolescence is a sensitive period for neurodevelopment, elucidating the role of primary dysmenorrhea in pain chronicity in future longitudinal studies is important for preventing both chronic pelvic and nonpelvic pain,” the researchers said.

Data for this study were sourced from PubMed, Embase, and Cinahl from inception to December 2019. Observational population-based studies analysing the relationship between dysmenorrhea and the presence or severity of chronic pain were included. Each study was double coded and assessed for bias based on the modified Newcastle and Ottawa Scale.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 12 Jan 2021
Adding the CDK4/6 inhibitor abemaciclib to an endocrine therapy of fulvestrant extends overall survival (OS) compared with fulvestrant alone in East Asian patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who have progressed on prior endocrine therapy, consistent with results from the overall population, updated analysis of the global, phase III MONARCH 2 study has shown.